Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Ovid Therapeutics Inc.

NASDAQ: OVID · Life Sciences · 2 alerts · CIK 1636651

Share price
$2.40Close, Nov 16
Market cap
$453M
Shares outstanding
188.73MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Ovid Therapeutics Inc. filings on SEC EDGAR ↗

7:06 AM ET 10-Q
Financial Results

Ovid Therapeutics Q3 2026 Results: Net Loss of $20.8M, Loss Widens

Ovid Therapeutics reported a net loss of $52.8 million for the nine months ended September 30, 2026, compared to a $27.1 million loss in the prior year period. The increase in loss was primarily driven by a significant rise in research and development expenses, which grew from $19.0 million to $36.8 million year-over-year.

Key figure
Net loss $20.8M
7:03 AM ET 8-K
Financial Results

Ovid Therapeutics Financial Results

Ovid Therapeutics reported third quarter 2026 financial results, ending the period with $161.4 million in cash and marketable securities. The company highlighted clinical progress for OV329 in focal epilepsy and the initiation of a Phase 1 study for OV4071, with a projected financial runway extending into 2029.

Term
Q3 2026

“The third quarter was focused on execution toward multiple, near-term clinical milestones across our pipeline. We anticipate findings from two high potential programs in early 2027, which may respectively demonstrate the broad potential of KCC2 direct activation and the anticonvulsant profile of OV329, a next-generation GABA-AT inhibitor.”

Meg Alexander, President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.